284 related articles for article (PubMed ID: 29922914)
1. Association between quality of life and clinical characteristics in patients with morphea.
Bali G; Kárpáti S; Sárdy M; Brodszky V; Hidvégi B; Rencz F
Qual Life Res; 2018 Oct; 27(10):2525-2532. PubMed ID: 29922914
[TBL] [Abstract][Full Text] [Related]
2. The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population.
Kelsey CE; Torok KS
J Am Acad Dermatol; 2013 Aug; 69(2):214-20. PubMed ID: 23562760
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature.
Szczęch J; Samotij D; Jaworecka K; Tobiasz A; Reich A
Biomed Res Int; 2020; 2020():9186274. PubMed ID: 32258158
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort.
Condie D; Grabell D; Jacobe H
Arthritis Rheumatol; 2014 Dec; 66(12):3496-504. PubMed ID: 25156342
[TBL] [Abstract][Full Text] [Related]
5. Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma.
Agazzi A; Fadanelli G; Vittadello F; Zulian F; Martini G
Pediatr Rheumatol Online J; 2018 Jun; 16(1):37. PubMed ID: 29914516
[TBL] [Abstract][Full Text] [Related]
6. Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change.
Teske NM; Jacobe HT
Br J Dermatol; 2020 Feb; 182(2):398-404. PubMed ID: 31049928
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in morphoea.
Klimas NK; Shedd AD; Bernstein IH; Jacobe H
Br J Dermatol; 2015; 172(5):1329-37. PubMed ID: 25483169
[TBL] [Abstract][Full Text] [Related]
8. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea.
Rencz F; Gulácsi L; Péntek M; Szegedi A; Remenyik É; Bata-Csörgő Z; Bali G; Hidvégi B; Tamási B; Poór AK; Hajdu K; Holló P; Kinyó Á; Sárdy M; Brodszky V
Br J Dermatol; 2020 May; 182(5):1167-1175. PubMed ID: 31419310
[TBL] [Abstract][Full Text] [Related]
9. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.
Arkachaisri T; Vilaiyuk S; Torok KS; Medsger TA
Rheumatology (Oxford); 2010 Feb; 49(2):373-81. PubMed ID: 20008472
[TBL] [Abstract][Full Text] [Related]
10. Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study.
Skrzypek-Salamon A; Lis-Święty A; Ranosz-Janicka I; Brzezińska-Wcisło L
Health Qual Life Outcomes; 2018 Sep; 16(1):185. PubMed ID: 30217204
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular Polydeoxyribonucleotides in Fibrotic and Atrophic Localized Scleroderma: An Explorative Prospective Cohort Study.
Romagnuolo M; Moltrasio C; Marzano AV; Nazzaro G; Muratori S; Recalcati S
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189808
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of health-related quality of life in psoriasis patients in Hungary].
Poór AK; Sárdy M; Cserni T; Brodszky V; Holló P; Gulácsi L; Remenyik É; Szegedi A; Rencz F; Péntek M
Orv Hetil; 2018 May; 159(21):837-846. PubMed ID: 29779387
[TBL] [Abstract][Full Text] [Related]
13. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
Daudén E; Pujol RM; Sánchez-Carazo JL; Toribio J; Vanaclocha F; Puig L; Yébenes M; Sabater E; Casado MA; Caloto MT; Aragón B;
Actas Dermosifiliogr; 2013 Nov; 104(9):807-14. PubMed ID: 23827342
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life in Chronic Pruritus: An Analysis Related to Disease Etiology, Clinical Skin Conditions and Itch Intensity.
Warlich B; Fritz F; Osada N; Bruland P; Stumpf A; Schneider G; Dugas M; Pfleiderer B; Ständer S
Dermatology; 2015; 231(3):253-9. PubMed ID: 26278551
[TBL] [Abstract][Full Text] [Related]
15. Dermatology life quality index in Thai patients with systemic sclerosis: a cross-sectional study.
Chularojanamontri L; Sethabutra P; Kulthanan K; Manapajon A
Indian J Dermatol Venereol Leprol; 2011; 77(6):683-7. PubMed ID: 22016275
[TBL] [Abstract][Full Text] [Related]
16. Morphea patients with mucocutaneous involvement: A cross-sectional study from the Morphea in Adults and Children (MAC) cohort.
Prasad S; Black SM; Zhu JL; Sharma S; Jacobe H
J Am Acad Dermatol; 2021 Jul; 85(1):114-120. PubMed ID: 33249064
[TBL] [Abstract][Full Text] [Related]
17. Psychological distress in patients with morphea and eosinophilic fasciitis.
Kroft EB; de Jong EM; Evers AW
Arch Dermatol; 2009 Sep; 145(9):1017-22. PubMed ID: 19770441
[TBL] [Abstract][Full Text] [Related]
18. Color Doppler Ultrasound Assessment of Subclinical Activity With Scoring of Morphea.
Parra-Cares J; Wortsman X; Alfaro-Sepúlveda D; Mellado-Francisco G; Ramírez-Cornejo C; Vera-Kellet C
J Cutan Med Surg; 2023; 27(5):454-460. PubMed ID: 37533149
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea.
García-Romero MT; Tollefson M; Pope E; Brandling-Bennett HA; Paller AS; Keimig E; Arkin L; Wanat KA; Humphrey SR; Werth VP; Oza V; Jacobe H; Fett N; Cordoro KM; Medina-Vera I; Chiu YE
JAMA Dermatol; 2023 Mar; 159(3):299-307. PubMed ID: 36753150
[TBL] [Abstract][Full Text] [Related]
20. Determinants of health-related quality of life in psoriasis patients in Malaysia.
Nyunt WW; Low WY; Ismail R; Sockalingam S; Min AK
Asia Pac J Public Health; 2015 Mar; 27(2):NP662-73. PubMed ID: 23858523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
